Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research

详细信息    查看全文

• 作者：Liza J McCann (1)
  Katie Arnold (2)
  Clarissa A Pilkington (2) (4)
  Adam M Huber (5)
  Angelo Ravelli (6)
  Laura Beard (2)
  Michael W Beresford (1) (7)
  Lucy R Wedderburn (2) (3) (4)
  the UK Juvenile Dermatomyositis Research Group (JDRG) (4)
  
  1. Alder Hey Children鈥檚 NHS Foundation Trust ; Eaton Road ; Liverpool ; L12 2AP ; UK
  2. Rheumatology Unit ; UCL Institute of Child Health ; University College London ; London ; UK
  4. Great Ormond Street Hospital ; London ; UK
  5. IWK Health Centre and Dalhousie University ; 5850 University Avenue ; Halifax ; NS ; B3K 6R8 ; Canada
  6. Universit脿 degli Studi di Genova and Istituto Giannina Gaslini ; Largo G. Gaslini 5 ; 16147 ; Genoa ; Italy
  7. Department of Women鈥檚 and Children鈥檚 Health ; Institute of Translational Medicine ; University of Liverpool ; Liverpool ; UK
  3. Centre for Adolescent Rheumatology at University College London ; University College London Hospital ; London ; UK
  
• 关键词：Juvenile dermatomyositis ; Idiopathic Inflammatory myopathy ; International ; Collaboration ; Dataset ; Core set ; Disease activity
• 刊名：Pediatric Rheumatology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：12
• 期：1
• 全文大小：518 KB
• 参考文献：1. Ravelli, A, Trail, L, Ferrari, C, Ruperto, N, Pistorio, A, Pilkington, C, Maillard, S, Oliveira, SK, Sztajnbok, F, Cuttica, R, Beltramelli, M, Corona, F, Katsicas, MM, Russo, R, Ferriani, V, Burgos-Vargas, R, Magni-Manzoni, S, Solis-Valleoj, E, Bandeira, M, Zullian, F, Baca, V, Cortis, E, Falcini, F, Alessio, M, Alpigiani, MG, Gerloni, V, Saad-Magalhaes, C, Podda, R, Silva, CA, Lepore, L (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 62: pp. 63-72 CrossRef
  2. Mathiesen, PR, Zak, M, Herlin, T, Nielsen, SM (2010) Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 28: pp. 782-789
  3. Sanner, H, Kirkhus, E, Merckoll, E, Tollisen, A, Roisland, M, Lie, BA, Taraldsrud, E, Gran, JT, Flato, B (2010) Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case鈥揷ontrol study. Arthritis Care Res (Hoboken) 62: pp. 1103-1111 CrossRef
  4. Feldman, BM, Rider, LG, Reed, AM, Pachman, LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371: pp. 2201-2212 CrossRef
  5. Robinson, AB, Reed, AM (2011) Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 7: pp. 664-675 CrossRef
  6. Symmons, DP, Sills, JA, Davis, SM (1995) The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 34: pp. 732-736 CrossRef
  7. Mendez, EP, Lipton, R, Ramsey-Goldman, R, Roettcher, P, Bowyer, S, Dyer, A, Pachman, LM (2003) US incidence of juvenile dermatomyositis, 1995鈥?998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49: pp. 300-305 CrossRef
  8. Oddis, CV, Reed, AM, Aggarwal, R, Rider, LG, Ascherman, DP, Levesque, MC, Barohn, RJ, Feldman, BM, Harris-Love, MO, Koontz, DC, Fertig, N, Kelley, SS, Pryber, SL, Miller, FW, Rockette, HE (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65: pp. 314-324 CrossRef
  9. Ruperto, N, Pistorio, A, Oliveira, S, Cuttica, RJ, Ravelli, A, Fischbach, M, Hagelberg, S, Avcin, A, Cheuret, E, Corona, F, Couillault, G, Dressler, F, Gerloni, V, Sterba, G, Zulian, F, Apaz, MT, Cespedes-Cruz, A, Cimaz, R, Bracaglia, C, Joos, R, Quartier, P, Russo, R, Tardieu, M, Wulfraat, N, Angioloni, S, Martini, A (2012) A randomised trial in new onset juvenile dermatomyositis: prednisolone versus prednisolone plus cyclosporine verus prednisolone plus methotrexate. [abstract]. Arthritis Rheum 64: pp. 2473 CrossRef
  10. Rider, LG, Giannini, EH, Harris-Love, M, Joe, G, Isenberg, D, Pilkington, C, Lachenbruch, PA, Miller, FW (2003) Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol 30: pp. 603-617
  11. Rider, LG, Giannini, EH, Brunner, HI, Ruperto, N, James-Newton, L, Reed, AM, Lachenbruch, PA, Miller, FW (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50: pp. 2281-2290 CrossRef
  12. Oddis, CV, Rider, LG, Reed, AM, Ruperto, N, Brunner, HI, Koneru, B, Feldman, BM, Giannini, EH, Miller, FW (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52: pp. 2607-2615 CrossRef
  13. Ruperto, N, Ravelli, A, Pistorio, A, Ferriani, V, Calvo, I, Ganser, G, Brunner, J, Dannecker, G, Silva, CA, Stanevicha, V, Cate, RT, van Suijlekom-Smit, LW, Voygioyka, O, Fischbach, M, Foeldvari, I, Hilario, O, Modesto, C, Saurenmann, RK, Sauvain, MJ, Scheibel, I, Sommelet, D, Tambic-Bukovac, L, Barcellona, R, Brik, R, Ehl, S, Jovanovic, M, Rovensky, J, Bagnasco, F, Lovell, DJ, Martini, A (2008) The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59: pp. 4-13 CrossRef
  14. Ruperto, N, Pistorio, A, Ravelli, A, Rider, LG, Pilkington, C, Oliveira, S, Wulffraat, N, Espada, G, Garay, S, Cuttica, R, Hofer, M, Quartier, P, Melo-Gomes, J, Reed, AM, Wierzbowska, M, Feldman, BM, Harjacek, M, Huppertz, HI, Nielsen, S, Flato, B, Lahdenne, P, Michels, H, Murray, KJ, Punaro, L, Rennebohm, R, Russo, R, Balogh, Z, Rooney, M, Pachman, LM, Wallace, C (2010) The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 62: pp. 1533-1541 CrossRef
  15. Ruperto, N, Ravelli, A, Murray, KJ, Lovell, DJ, Andersson-Gare, B, Feldman, BM, Garay, S, Kuis, W, Machado, C, Pachman, L, Prieur, AM, Rider, LG, Silverman, E, Tsitsami, E, Woo, P, Giannini, EH, Martini, A (2003) Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 42: pp. 1452-1459 CrossRef
  16. Lundberg, IE, Svensson, J (2013) Registries in idiopathic inflammatory myopathies. Curr Opin Rheumatol 25: pp. 729-734 CrossRef
  17. Lionetti, G, Kimura, Y, Schanberg, LE, Beukelman, T, Wallace, CA, Ilowite, NT, Winsor, J, Fox, K, Natter, M, Sundy, JS, Brodsky, E, Curtis, JR, Del Gaizo, V, Iyasu, S, Jahreis, A, Meeker-O'Connell, A, Mittleman, BB, Murphy, BM, Peterson, ED, Raymond, SC, Setoguchi, S, Siegel, JN, Sobel, RE, Solomon, D, Southwood, TR, Vesely, R, White, PH, Wulffraat, NM, Sandborg, CI (2013) Using registries to identify adverse events in rheumatic diseases. Pediatrics 132: pp. e1384-e1394 CrossRef
  18. Martin, N, Krol, P, Smith, S, Murray, K, Pilkington, CA, Davidson, JE, Wedderburn, LR (2011) A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10聽years鈥?experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford) 50: pp. 137-145 CrossRef
  19. Natter, MD, Quan, J, Ortiz, DM, Bousvaros, A, Ilowite, NT, Inman, CJ, Marsolo, K, McMurry, AJ, Sandborg, CI, Schanberg, LE, Wallace, CA, Warren, RW, Weber, GM, Mandl, KD (2013) An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc 20: pp. 172-179 CrossRef
  20. Robinson, AB, Hoeltzel, MF, Wahezi, DM, Becker, ML, Kessler, E, Schmeling, H, Carrasco, R, Huber, AM, Feldman, BM, Reed, AM (2013) Clinical characteristics of children with juvenile dermatomyositis - the children鈥檚 arthritis and rheumatology research alliance (CARRA) registry. Arthritis Care Res (Hoboken).
  21. McCann, LJPCA, Beard, L, Ravelli, A, Huber, A, Wedderburn, LR (2011) Proposal for the development of an international minimal data collection for juvenile dermatomyositis [abstract]. Arthritis Rheum 61: pp. 234
  22. Dugan, EM, Huber, AM, Miller, FW, Rider, LG (2009) Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 15: pp. 1
  23. Rider, LG, Werth, VP, Huber, AM, Alexanderson, H, Rao, AP, Ruperto, N, Herbelin, L, Barohn, R, Isenberg, D, Miller, FW (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 63: pp. S118-S157 CrossRef
  24. Wedderburn, LR, McHugh, NJ, Chinoy, H, Cooper, RG, Salway, F, Ollier, WE, McCann, LJ, Varsani, H, Dunphy, J, North, J, Davidson, JE (2007) HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 46: pp. 1786-1791 CrossRef
  25. Tansley, SL, McHugh, NJ, Wedderburn, LR (2013) Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther 15: pp. 211 CrossRef
  26. Alemo Munters, L, van Vollenhoven, RF, Alexanderson, H (2011) Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis. ISRN Rheumatol 2011: pp. 463124 CrossRef
  27. Filocamo, G, Consolaro, A, Ferrari, C, Ravelli, A (2013) Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clin Exp Rheumatol 31: pp. 964-968
  28. Huber, AM, Giannini, EH, Bowyer, SL, Kim, S, Lang, B, Lindsley, CB, Pachman, LM, Pilkington, C, Reed, AM, Rennebohm, LG, Rider, RM, Wallace, CA, Feldman, BA (2010) Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children鈥檚 Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 62: pp. 219-225 CrossRef
  29. Lazarevic, D, Pistorio, A, Palmisani, E, Miettunen, P, Ravelli, A, Pilkington, C, Wulffraat, NM, Malattia, C, Garay, SM, Hofer, M, Quartier, P, Dolezalova, P, Penades, IC, Ferriani, VP, Ganser, G, Kasapcopur, O, Melo-Gomes, JA, Reed, AM, Wierzbowska, M, Rider, LG, Martini, A, Ruperto, N (2013) The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 72: pp. 686-693 CrossRef
  30. Wulffraat, NM, Vastert, B (2013) Time to share. Pediatr Rheumatol Online J 11: pp. 5 CrossRef
  31. Bohan, A, Peter, JB (1975) Polymyositis and dermatomyositis. Parts 1 and 2. New Engl J Med 292: pp. 344-347 CrossRef
  32. / Washington Neuromuscular Disease Centre. [http://neuromuscular.wustl.edu]
  33. Santmyire-Rosenberger, B, Dugan, EM (2003) Skin Involvement in Dermatomyositis. Curr Opin Rheumatol 15: pp. 714-722 CrossRef
  34. Lovell, DJ, Lindsley, CB, Rennebohm, RM, Ballinger, SH, Bowyer, SL, Giannini, EH, Hicks, JE, Levinson, JE, Mier, R, Pachman, LM, Passo, MH, Perez, MD, Reed, AM, Schikler, KN, Smith, M, Zemel, LS, Rider, LG (1999) Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 42: pp. 2213-2219 CrossRef
  35. Huber, AM, Lovell, DJ, Pilkington, CA, Rennebohm, RM, Rider, LG (2013) Confusion concerning multiple versions of the Childhood Myositis Assessment Scale. Arthritis Care Res.
  36. Nugent, J, Ruperto, N, Grainger, J, Machado, C, Sawhney, S, Baildam, E, Davidson, J, Foster, H, Hall, A, Hollingworth, P, Sills, J, Venning, H, Walsh, JE, Landgraf, JM, Roland, M, Woo, P, Murray, KJ (2001) The British version of the Childhood Health assessment questionnaire (CHAQ) and the child health Questionnaire (CHQ). Clin Exp Rheumatol 2001: pp. S163-S167
  37. Huber, AM, Hicks, JE, Lachenbruch, PA, Perez, MD, Zemel, LS, Rennebohm, RM, Wallace, CA, Lindsley, CB, Passo, MH, Ballinger, SH, Bowyer, SL, Reed, AM, White, PH, Katona, IM, Miller, FW, Rider, LG, Feldman, BM (2001) Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 28: pp. 1106-1111
  
• 刊物主题：Pediatrics; Rheumatology;
• 出版者：BioMed Central
• ISSN：1546-0096

文摘

Background Juvenile dermatomyositis (JDM) is a rare but severe autoimmune inflammatory myositis of childhood. International collaboration is essential in order to undertake clinical trials, understand the disease and improve long-term outcome. The aim of this study was to propose from existing collaborative initiatives a preliminary minimal dataset for JDM. This will form the basis of the future development of an international consensus-approved minimum core dataset to be used both in clinical care and inform research, allowing integration of data between centres. Methods A working group of internationally-representative JDM experts was formed to develop a provisional minimal dataset. Clinical and laboratory variables contained within current national and international collaborative databases of patients with idiopathic inflammatory myopathies were scrutinised. Judgements were informed by published literature and a more detailed analysis of the Juvenile Dermatomyositis Cohort Biomarker Study and Repository, UK and Ireland. Results A provisional minimal JDM dataset has been produced, with an associated glossary of definitions. The provisional minimal dataset will request information at time of patient diagnosis and during on-going prospective follow up. At time of patient diagnosis, information will be requested on patient demographics, diagnostic criteria and treatments given prior to diagnosis. During on-going prospective follow-up, variables will include the presence of active muscle or skin disease, major organ involvement or constitutional symptoms, investigations, treatment, physician global assessments and patient reported outcome measures. Conclusions An internationally agreed minimal dataset has the potential to significantly enhance collaboration, allow effective communication between groups, provide a minimal standard of care and enable analysis of the largest possible number of JDM patients to provide a greater understanding of this disease. This preliminary dataset can now be developed into a consensus-approved minimum core dataset and tested in a wider setting with the aim of achieving international agreement.